Amide and ester derivatives of chlorido[4-carboxy-1,2-disalicylideneaminobenzene]iron(iii) as necroptosis and ferroptosis inducers.


Journal

Dalton transactions (Cambridge, England : 2003)
ISSN: 1477-9234
Titre abrégé: Dalton Trans
Pays: England
ID NLM: 101176026

Informations de publication

Date de publication:
26 May 2020
Historique:
pubmed: 8 5 2020
medline: 15 1 2021
entrez: 8 5 2020
Statut: ppublish

Résumé

In continuation of the structure-activity study about 4-substituted chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(iii) complexes as necroptosis and ferroptosis inducers, we introduced a 4-COOH group at the 1,2-phenylenediamine moiety of the lead ([Fe(iii)salopheneCl]) and derived the resulting complex 15 to the respective ethyl, propyl, or butyl amides (16-18) and esters (19-21). The compounds 16-21 exerted concentration-dependent antiproliferative and antimetabolic effects against HL-60 cells. The esters were more active than the analogous amides. Elongation of the alkyl chain enhanced the activity of the amides, while that of the esters decreased. The complexes 16-21 induced necroptosis and/or ferroptosis but not apoptosis. Studies on protein binding and uptake into HL-60 cells indicated that the complexes mainly accumulated by passive transport. The high binding tendency of all complexes to apo-Transferrin, however, points to participation of a carrier-mediated transport into the cells, too.

Identifiants

pubmed: 32377663
doi: 10.1039/d0dt00168f
doi:

Substances chimiques

Amides 0
Antineoplastic Agents 0
Esters 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6842-6853

Auteurs

Daniel Baecker (D)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Benjamin N Ma (BN)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Jessica Sagasser (J)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Lukas Schultz (L)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Carina Hörschläger (C)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Maria Weinreich (M)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Lucy Steiner (L)

Immunobiology and Stem Cell Laboratory, Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria and Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria.

Brigitte Kircher (B)

Immunobiology and Stem Cell Laboratory, Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria and Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria.

Ronald Gust (R)

Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, CCB - Center for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria. ronald.gust@uibk.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH